These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25389223)

  • 1. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
    Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
    J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
    Kaur J; Sundar S; Singh N
    J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
    Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
    J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
    Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
    J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
    Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D
    Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Franzblau SG; Wan B; Wang Y; Ma Z; Cooper CB; Denny WA
    J Med Chem; 2017 May; 60(10):4212-4233. PubMed ID: 28459575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis.
    Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D
    Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
    Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
    Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
    Thompson AM; O'Connor PD; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Martin D; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
    J Med Chem; 2016 Mar; 59(6):2530-50. PubMed ID: 26901446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis.
    Paik D; Pramanik PK; Chakraborti T
    Int Immunopharmacol; 2020 Aug; 85():106623. PubMed ID: 32504996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel arylimidamides for treatment of visceral leishmaniasis.
    Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Amino acid derivatives as mitochondrial complex III inhibitors of L. donovani: A promising chemotype targeting visceral leishmaniasis.
    Chandrakar P; Gunaganti N; Parmar N; Kumar A; Singh SK; Rashid M; Wahajuddin M; Mitra K; Narender T; Kar S
    Eur J Med Chem; 2019 Nov; 182():111632. PubMed ID: 31499363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antileishmanial and immunomodulatory activities of lupeol, a triterpene compound isolated from Sterculia villosa.
    Das A; Jawed JJ; Das MC; Sandhu P; De UC; Dinda B; Akhter Y; Bhattacharjee S
    Int J Antimicrob Agents; 2017 Oct; 50(4):512-522. PubMed ID: 28669838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
    Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
    J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis.
    Khanra S; Juin SK; Jawed JJ; Ghosh S; Dutta S; Nabi SA; Dash J; Dasgupta D; Majumdar S; Banerjee R
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008575. PubMed ID: 32866156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromone linked nitrone derivative induces the expression of iNOS2 and Th1 cytokines but reduces the Th2 response in experimental visceral leishmaniasis.
    Mallick S; Halder S; Dutta A; Dey S; Paul K; Maiti S; Bandyopadhyay C; Saha B; Pal C
    Int Immunopharmacol; 2013 Apr; 15(4):772-9. PubMed ID: 23499679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response.
    Melby PC; Chandrasekar B; Zhao W; Coe JE
    J Immunol; 2001 Feb; 166(3):1912-20. PubMed ID: 11160239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of artemisinin in experimental visceral leishmaniasis.
    Sen R; Ganguly S; Saha P; Chatterjee M
    Int J Antimicrob Agents; 2010 Jul; 36(1):43-9. PubMed ID: 20403680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.